U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07705737) titled 'Rademikibart IV for Acute Asthma and COPD Exacerbation' on July 10.
Brief Summary: A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Asthma Acute
COPD Exacerbation Acute
Intervention:
DRUG: Rademikibart
Single 300 mg dose as a 2-minute IV push
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Connect Biopharm LLC
Published by HT Digital Content Services with permission from Health Daily Digest....